KDM6A and neoplasm: In an available gene expression dataset from tumor specimens of HNSCC patients treated with primary radio/chemotherapy (n = 137, DKTK-ROG) [23], we analyzed the clinical potential of KDM6A (UTX) and KDM6B (JMJD3) as putative prognostic biomarkers and stratified patients into high and low expression groups based on median gene expression values.